{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:09Z","timestamp":1787026569924,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lung cancer, particularly non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related mortality worldwide. While immune checkpoint blockade (ICB), such as PD-1\/PD-L1 inhibitors, have revolutionized treatment for advanced NSCLC, not all tumor patients respond to ICB therapy. Our recent investigations highlight the role of collagens synthesized by cancer-associated fibroblasts (CAFs) in immune evasion. Angiotensin II receptor blocker (ARB) has shown potential in reshaping the tumor microenvironment (TME) by inhibiting collagens, making tumors more susceptible to immunotherapy. This study aims to evaluate the effect of ARB on the efficacy and safety of Camrelizumab, an anti-PD-1 antibody, in combination with chemotherapy for first-line treatment of advanced NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The ARMOR I trial is a prospective, real-world, multicenter, intervention clinical study designed to assess the synergistic effect of ARBs on Camrelizumab plus chemotherapy in patients with advanced NSCLC. Eligible patients include those with stage IV or unresectable locally advanced NSCLC, who have been diagnosed with hypertension and are receiving standard treatment for it. The study will enroll approximately 180 patients over a 12-month recruitment period, with a 12-month follow-up phase. The primary endpoint is the objective response rate (ORR), with secondary endpoints including progression-free survival (PFS), overall survival (OS), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The interplay between collagens, ARB, and cancer is still complex and worth further study. ARMOR I will provide crucial preliminary data on ARB\u2019s role in first-line therapy for advanced NSCLC. The potential application of ARB in other tumor types may also become an important area to explore.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1668782","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T05:10:34Z","timestamp":1762837834000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of angiotensin II receptor blockers on efficacy and safety of Camrelizumab plus chemotherapy in the first-line therapy for advanced non-small cell lung cancer (ARMOR I): a protocol for a prospective, real-world, multicenter, intervention clinical trial"],"prefix":"10.3389","volume":"16","author":[{"given":"Zeyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huning","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanfang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105110","article-title":"Hsa-miR-4271 downregulates the expression of constitutive androstane receptor and enhances in vivo the sensitivity of non-small cell lung cancer to gefitinib","volume":"161","author":"Wang","year":"2020","journal-title":"Pharmacol Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.09.010","article-title":"The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation","volume":"12","author":"Fan","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102640","article-title":"61P First-line camrelizumab (Camre) plus carboplatin (Carbo) and pemetrexed (Pem) for advanced non-squamous NSCLC: 5-yr outcomes of CameL phase III study","volume":"9","author":"Zhou","year":"2024","journal-title":"ESMO Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102641","article-title":"62P First-line (1L) camrelizumab plus chemotherapy (chemo) for advanced squamous non-small cell lung cancer (sqNSCLC): 4-yr update from the phase III CameL-sq trial","volume":"9","author":"Zhou","year":"2024","journal-title":"ESMO Open"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041189","article-title":"Modulating T cell responses by targeting CD3","volume":"15","author":"Menon","year":"2023","journal-title":"Cancers"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2019.08.002","article-title":"Cancer and the immune system: the history and background of immunotherapy","volume":"35","author":"Abbott","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106966","article-title":"The clinical and immune features of CD14 in colorectal cancer identified via large-scale analysis","volume":"88","author":"Chen","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12538","article-title":"Conserved immuno-collagenic subtypes predict response to immune checkpoint blockade","volume":"44","author":"Mei","year":"2024","journal-title":"Cancer Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-0569","article-title":"The complex integration of T-cell metabolism and immunotherapy","volume":"11","author":"Madden","year":"2021","journal-title":"Cancer Discov"},{"key":"B14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jconrel.2024.06.016","article-title":"Hybrid nanopotentiators with dual cascade amplification for glioma combined interventional therapy","volume":"372","author":"Ye","year":"2024","journal-title":"J Control Release"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18298-8","article-title":"Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion","volume":"11","author":"Peng","year":"2020","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/pgpm.s399886","article-title":"Nidogen-2 (NID2) is a key factor in collagen causing poor response to immunotherapy in melanoma","volume":"16","author":"Sha","year":"2023","journal-title":"PGPM"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111782","article-title":"A novel GARP humanized mouse model for efficacy assessment of GARP-targeting therapies","volume":"130","author":"Guo","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1200\/edbk_237641","article-title":"A practical guide to geriatric syndromes in older adults with cancer: A focus on falls, cognition, polypharmacy, and depression","volume":"39","author":"Magnuson","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/4735876","article-title":"Prescribing patterns of antihypertensives for treatment-na\u00efve patients in South Korea: from korean NHISS claim data","volume":"2019","author":"Kim","year":"2019","journal-title":"Int J Hypertens"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-50224-9_7","article-title":"Renin\u2013angiotensin system in the tumor microenvironment","author":"Nakamura","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106507","article-title":"Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma","volume":"84","author":"Yang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2021.04.006","article-title":"Structural insights into ligand recognition and activation of angiotensin receptors","volume":"42","author":"Zhang","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e009327","DOI":"10.1136\/jitc-2024-009327","article-title":"Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade","volume":"12","author":"Mei","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.836934","article-title":"Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity","volume":"12","author":"Sieber","year":"2020","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.medj.2024.02.012","article-title":"Nanodrug-bacteria conjugates-mediated oncogenic collagen depletion enhances immune checkpoint blockade therapy against pancreatic cancer","volume":"5","author":"Li","year":"2024","journal-title":"Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900789","article-title":"Collagen density modulates the immunosuppressive functions of macrophages","volume":"205","author":"Larsen","year":"2020","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.015","article-title":"Activated fibroblasts in cancer: Perspectives and challenges","volume":"41","author":"Caligiuri","year":"2023","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1018892108","article-title":"Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors","volume":"108","author":"Diop-Frimpong","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.canlet.2020.07.015","article-title":"Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation","volume":"493","author":"Wadsworth","year":"2020","journal-title":"Cancer Lett"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.216382","article-title":"Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis","volume":"350","author":"Alhusban","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00886-2","article-title":"Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13772-3","article-title":"Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects","volume":"12","author":"Tehrani","year":"2022","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.niox.2022.12.002","article-title":"Heterogenous improvements in endothelial function by sub-blood pressure lowering doses of ARBs result in major anti-aortic root remodeling effects","volume":"131","author":"Tehrani","year":"2022","journal-title":"Nitric Oxide"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1668782\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T05:10:37Z","timestamp":1762837837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1668782\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2025.1668782"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1668782","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"article-number":"1668782"}}